Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Anticancer Drugs
; 31(6): 652-654, 2020 07.
Article
en En
| MEDLINE
| ID: mdl-32011367
ABSTRACT
Mucosal melanoma is rare and accounts for 1.3-1.4% of all melanomas. Kit mutations are found in approximately 15-20% of mucosal melanomas. Immunotherapy with anti cytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death protein 1 have reported low clinical efficacy in this melanoma subtype. Studies with Kit inhibitor Imatinib showed response rates ranging from 20 to 30%. We present the case of a patient with a c-kit mutated metastatic melanoma who developed autoimmune vitiligo during treatment with oral tyrosine kinase inhibitor Masitinib.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Tiazoles
/
Vitíligo
/
Neoplasias de la Vulva
/
Proteínas Proto-Oncogénicas c-kit
/
Melanoma
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Anticancer Drugs
Asunto de la revista:
ANTINEOPLASICOS
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia